In 2010, there were an estimated 600 million daily tobacco smokers in the major Western + BRIC (Emerging markets).
According to the WHO, tobacco kills nearly six million people each year, of whom more than 5 million are users and ex users
and more than 600 000 are nonsmokers exposed to second-hand smoke. Nearly 80% of the world's one billion smokers live in
low- and middle-income countries.
Many smokers want to quit and several pharmacologic therapies for smoking cessation are available which can enhance quit
rates. These include direct nicotine replacement therapy (NRT), varenicline (Chantix) and bupropion (Zyban). Nicotine vaccines
are also being investigated which induce antibodies which bind nicotine in the blood preventing it from crossing the blood-brain
barrier. However, failure rate has been high with NABI's (GSK) NicVAX, Cytos's NicQb/NIC002 and Celtic Pharma's TA-NIC all
This MarketVIEW product contains a comprehensive MS Excel-based model + summary presentation which forecasts the
potential commercial value of smoking cessation nicotine vaccines across major Western1 and BRIC-MT markets until 2030. The
model contains value ($ m) and volume (mio doses) predictions per product type along with timeframe, pricing and penetration
estimates for target populations. The product also includes an in depth review of latest smoking epidemiological trends,
cessation treatments and latest developments in R&D.
THIS PRODUCT IS A EXECUTIVE PRESENTATION + 1 MODEL